Actively Recruiting
Evaluating Pembrolizumab with or without Tivozanib After Surgery for High-Risk Renal Cell Carcinoma
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-03
1040
Participants Needed
429
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the addition of tivozanib to standard pembrolizumab immunotherapy for patients with high-risk renal cell carcinoma RCC after surgery. This phase III trial aims to compare disease-free survival and overall survival between patients receiving pembrolizumab alone and those receiving pembrolizumab combined with tivozanib. The study also assesses side effects, patient quality of life, and will bank specimens for future research. Participants are randomly assigned to one of two groups. One group receives pembrolizumab intravenously on specific days every 12 weeks for up to 4 cycles. The other group receives pembrolizumab on the same schedule plus oral tivozanib daily on specified days within each cycle for up to 6 months. Both groups undergo regular blood sample collection and imaging scans like MRI or CT, and may have tissue biopsies during the study. After treatment, participants are followed with visits every 4 months for 2 years, then every 6 months for 3 years, and annually for 5 more years. Researchers monitor disease recurrence, survival, side effects, and treatment tolerance. Patient-reported fatigue and overall quality of life are also measured throughout the study to understand the impact of the treatments over time.
CONDITIONS
Brief Title
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Research Team
A
Aishwarya Vijendran
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here